article thumbnail

Can genetic data be a magic bullet for drug R&D?

pharmaphorum

The same is becoming true for the healthcare industry, and one of the first major breakthroughs in the area was the 100,000 Genomes Project. The information gathered from the project is still providing insights today, a decade later.

article thumbnail

Unlocking disease treatment with large-scale research

pharmaphorum

A few decades ago, gathering genetic data on the scale of the 100,000 Genomes Project would have been unthinkable – it was only in 2003 that the entire human genome was mapped. It is likely, just as with the 100,000 Genomes Project, we will be hearing about the breakthrough made possible by this approach in the years to come.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

Despite the overall reduction in major pharma R&D centres in the UK, global pharma companies continue to engage with academic and biotech organisations here, particularly in hotspots such as the Golden Triangle, the Northwest, and Scotland, through the strong networks that have been developed between these organisations.

Drugs 75
article thumbnail

Open science, genomics, and the quiet revolution in our approach to pharma

Drug Discovery World

Increasingly, major collaborative life sciences projects, like the Human Genome Project or Human Cell Atlas, are driving advancements and organisations – both public and private – are taking note. The post Open science, genomics, and the quiet revolution in our approach to pharma appeared first on Drug Discovery World (DDW).

Genome 52